

News Release

December 14, 2023
Carna Biosciences, Inc.

Carna Receives Second Milestone Payment from Gilead

Carna Biosciences, Inc. (NASDAQ: 4572), a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, today announced that the company received a second milestone payment of \$5 million from Gilead Sciences, Inc. (NASDAQ: GILD) under the license agreement to develop and commercialize small molecule compounds in immuno-oncology. The payment was triggered by the initiation of Phase 1 clinical trials of GS-9911, an investigational DGK α inhibitor, developed by Gilead under the license and research collaboration.

"DGK α has emerged as an attractive drug target to modulate T-cell antitumor immunity, and a DGK α inhibitor has a potential to pioneer the next generation of cancer immunotherapy. GS-9911 is an investigational selective and potent DGK α inhibitor developed through our collaboration with Gilead, and we believe it could provide a profound benefit for cancer patients who need new therapies.," said Kohichiro Yoshino, Ph.D., President and Chief Executive Officer at Carna Biosciences.

Under the terms of the license agreement entered into in June 2019, Carna licensed to Gilead worldwide rights to develop and commercialize small molecule compounds in immuno-oncology. In connection with this agreement, Carna received an upfront payment of \$20 million and is eligible to receive up to an additional \$450 million in potential milestone payments upon achievement of certain development and commercial milestones. Carna will also receive royalties on future net sales. The first milestone payment has paid to Carna from Gilead in December 2021, and Carna received the second milestone payment from Gilead in 2023.

Contact:
Corporate Planning
Carna Biosciences, Inc.
TEL: +81-78-302-7075
<https://www.carnabio.com/english/>